Sensato Investors’s Haemonetics HAE Stock Holding History

Sensato Investors’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-21,700	Closed	-$1.95M	–	103
2018 Q2	$1.95M	Buy	+21,700	New	+$1.83M	0.3%	51

Other funds holding HAE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Sensato Investors's HAE Position: Q3 2018 in Review

Sensato Investors sold out of Haemonetics (HAE) in Q3 2018, closing a stake of 21,700 shares — an estimated $1.95M sold.

Sensato Investors first reported a position in HAE in Q2 2018 and held it in 1 quarter. The position peaked at $1.95M in Q2 2018. 292 funds tracked by Wall St. Rank hold HAE as of Q3 2018.

Sensato Investors reported no remaining Haemonetics position as of Q3 2018 after selling out during the quarter.
Sensato Investors sold 21,700 Haemonetics shares in Q3 2018, an estimated $1.95M.
Sensato Investors first reported a position in Haemonetics in Q2 2018 and held it in 1 quarter.
Sensato Investors's Haemonetics position peaked at $1.95M in Q2 2018.
292 funds tracked by Wall St. Rank held Haemonetics as of Q3 2018.

Based on Sensato Investors's 13F filing for Q3 2018, filed 14 Nov 2018.